PATRegistry-verifiedPrivate-market model

Zentralinstitut für Seelische Gesundheit (ZI) Mannheim

Mannheim, Germany

Treatment & access

Treatments offeredPsilocybin
Access routeCompassionate-use programme
Cost & coverage (registry status)No price published for Compassionate Use treatment; psilocybin (PEX010) supplied within the authorised Expanded Access Programme; treatment inpatient-only at a public-mandate institution
Phone+49 621 1703-0 (switchboard); +49 621 1703-2850 (Zentralambulanz, info & appointments 08:30-16:00)
Websitehttps://zi-mannheim.de

Related listings

These records belong to the same organisation. They are listed separately because each is a distinct programme or location.

Another programme at this clinicCentral Institute of Mental Health : Clinical trials
Another programme at this clinicZentralinstitut für Seelische Gesundheit (ZI) Mannheim — Studienzentrum : Clinical trials

About this provider

The Zentralinstitut fuer Seelische Gesundheit (Central Institute of Mental Health, CIMH) in Mannheim is one of Germany's leading psychiatric research and care institutions. Since 11 July 2025 it runs - together with the OVID day clinic in Berlin and under the direction of Prof. Dr. Gerhard Gruender (Dept. of Molecular Neuroimaging) - the first Compassionate Use / Expanded Access Programme for psilocybin in the European Union, for adults with treatment-resistant depression in justified exceptional cases. Treatment is inpatient-only: single doses of psilocybin (usually 25 mg, PEX010 by Filament Health) embedded in psychotherapeutic preparation and follow-up. CIMH led the EPIsoDE study (2021-2024, with Charite and the MIND Foundation), Germany's largest psilocybin TRD trial, and currently recruits for LSD (MM120) and deuterated-psilocin (CYB003) trials.

Services & programs

Psilocybin treatment for treatment-resistant depression within Compassionate Use / Expanded Access Programme (inpatient; single doses usually 25 mg + accompanying psychotherapy; outpatient appointments for eligibility check, preparation and follow-up)
Participation in psychedelic clinical trials (see programs)
General psychiatric care via Department of Psychiatry and Psychotherapy; Zentralambulanz (central outpatient intake); 24/7 psychiatric emergency service (+49 621 1703-7777)

Programs & studies

Program	Kind	Status
Expanded Access Programme (Compassionate Use) for psilocybin in treatment-resistant depression - first for this substance in the EU; sites: CIMH Mannheim and OVID day clinic Berlin; director Prof. Dr. Gerhard Gruender; drug PEX010 (botanical psilocybin) by Filament Health; approved by BfArM		active since 11 July 2025; exceptional cases only; substantial waiting list
MM120 (LSD-D-tartrate) for generalized anxiety disorder		recruitment started
CYB003 (deuterated psilocin) for major depressive disorder		recruitment started
EPIsoDE study - psilocybin 25 mg + psychotherapy for treatment-resistant unipolar depression (Jun 2021 - Dec 2024; CIMH lead, with Charite Berlin and MIND Foundation); ~30% response at 12 weeks; main results under journal review		completed

Pricing

Item	Price
Compassionate Use psilocybin treatment institutional charge schedule (PEPP-Entgelttarif 2026) published for inpatient psychiatric care generally	no price published on site

Prices are taken from the provider's own website and were last checked on 2026-07-09. Always confirm the current price with the provider before booking.

Facilities & languages

Facilities
- Campus at J 5, 68159 Mannheim
- Dedicated therapy rooms for psychedelic substance sessions (pictured on site)
- Inpatient wards (CU treatment exclusively inpatient)
- 24/7 emergency service
LanguagesGerman; full English website mirror
TeamProgramme director: Prof. Dr. Gerhard Gruender, Head of the Department of Molecular Neuroimaging at CIMH (submitted the successful BfArM application). Treatment team draws on experience from clinical psilocybin/psychedelics studies; in the EPIsoDE protocol participants were accompanied by two therapists during substance sessions.

Common questions

Who can be treated with psilocybin at ZI?

Individual adult patients with treatment-resistant depression, in justified exceptional cases only: serious illness, no satisfactory treatment with approved drugs, and no possibility of joining a clinical trial; each case gets a benefit-risk assessment.

How do I apply?

Contact psychedelika-studien@zi-mannheim.de (or the web form) with full contact details and consent to data storage; you are then placed on the waiting list.

How long is the wait?

The institute states it receives very many inquiries and that considerable waiting times can occur; demand is expected to significantly exceed capacity.

Is the treatment outpatient?

No - psilocybin treatment within the CU programme takes place exclusively on an inpatient basis, with additional outpatient appointments for eligibility, preparation and follow-up.

Can I get psilocybin outside the programme or trials?

No - classic psychedelics in Germany are only permitted within officially approved clinical trials or the Expanded Access Programme; they remain controlled under the BtMG otherwise.

1 more verified providers within 50 km

Alzey · 38 kmFacharztpraxis Dr. med. Jochen Klinga — Esketamin-Ambulanz : Spravato®

See them on the provider map →

Practical details

As stated on the provider's own website (checked 2026-09-09); details can change — confirm when you book.

Opening hoursInformation/Terminvergabe: 08:30–16:00 Source →
BookingDirect booking possible — the provider states no referral is required. Source →

Verification

At least one source for this record is a public state registry or an official public-law register. The registry entry is linked below and re-checked at least every 90 days.

License / registryDestatis Krankenhausverzeichnis 2024
Official registryhttps://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Gesundheit/Krankenhauser/krankenhausverzeichnis.html
Provider websitehttps://zi-mannheim.de
Provider websitehttps://www.zi-mannheim.de/behandlung/klinik-psychiatrie/psychedelika-in-psychiatrie-und-psychotherapie.html
Last verified2026-07-05

Individual treatment permits in Switzerland are issued by the FOPH (BAG) per patient and are not public: this listing reflects SÄPT training/membership plus a verified medical licence (MedReg).

Spotted an error? See our methodology for how records are checked and how to report a correction.

Check your fit & enquire

PAT access in Germany follows published criteria. A short pre-screening comes first, then your compiled summary goes to Zentralinstitut für Seelische Gesundheit (ZI) Mannheim only with your explicit consent, and you can download it for yourself either way.

Why enquire via PsyAccess

Pre-screening first. A 2-minute check in your browser shows which legal routes fit your situation, before you reach out to anyone.
A structured enquiry. Your enquiry reaches the provider with a structured summary, so the clinic can reply quickly and to the point.
Independent & free. Free for patients. We don't charge for enquiries, and no provider pays for placement.

Check my fit & enquire

About two minutes. The check itself runs in your browser: your answers are never sent anywhere unless you choose to send them. We count only anonymous usage events.

Check my fit & enquire